Lepu Biopharma Announces Major Milestone in Collaboration with AstraZeneca for ADC Candidate CMG901 (AZD0901)

Lepu Biopharma Co., Ltd. has released a significant update regarding its collaboration with AstraZeneca for the development and commercialization of the antibody-drug conjugate (ADC) candidate CMG901 (also known as sonesitatug vedotin or AZD0901). This development is highly relevant for shareholders and could have a notable impact on share value given the financial and clinical implications for the company’s pipeline and revenue prospects.

Key Highlights

• Initiation of Phase III Clinical Study: AstraZeneca has commenced a multi-center, randomized, controlled Phase III study of AZD0901 in combination with capecitabine, with or without rilvegostomig. The trial targets first-line treatment for Claudin 18.2-positive and HER2-negative advanced/metastatic gastric cancer, gastroesophageal junction cancer, or esophageal adenocarcinoma (CLARITY-Gastric 02). Importantly, the first subject has already received their initial dose.
• Milestone Payment Triggered: The dosing of the first subject in this pivotal clinical trial has triggered a milestone payment of US\$45 million from AstraZeneca to the Lepu Biopharma and Keymed joint venture, KYM Biosciences Inc. This is an immediate and material inflow of non-dilutive capital for the company.
• About CMG901 (AZD0901): CMG901 is a Claudin 18.2-targeting ADC comprised of a specific antibody, a cleavable linker, and the cytotoxic payload monomethyl auristatin E (MMAE). It is the first ADC targeting Claudin 18.2 to receive IND approval in both China and the United States. Claudin 18.2 is a highly selective marker widely expressed in gastric, pancreatic, and other solid tumors, representing a promising therapeutic target.
• Regulatory Progress and Designations: CMG901 has previously received a breakthrough therapy designation from China’s Center for Drug Evaluation (CDE) for advanced gastric cancer. In the United States, it has been granted both Orphan Drug Designation and Fast Track Designation by the FDA for relapsed/refractory gastric cancer and gastroesophageal junction adenocarcinoma.
• Ongoing and Planned Clinical Studies:
  • A multi-center, sponsor-blinded, randomized Phase III study (CLARITY-Gastric 01) comparing AZD0901 monotherapy to investigator’s choice in advanced/metastatic gastric cancer or gastroesophageal junction adenocarcinoma with Claudin 18.2 expression in patients who have previously received two or more lines of therapy.
  • Phase II open-label, multi-drug, multi-center GEMINI-PeriOp GC study to evaluate safety, tolerability, and efficacy in locally advanced, resectable gastroesophageal junction adenocarcinoma.
  • Phase II CLARITY-PanTumour01 studying monotherapy or combination regimens in Claudin 18.2-expressing advanced solid tumors (including gastric, pancreatic, and biliary tract cancer).
• About KYM Biosciences: KYM is a joint venture between Lepu Biopharma (30% ownership) and Keymed Biosciences (70% ownership), focused on CMG901’s development and commercialization.

Shareholder-Relevant and Price-Sensitive Information

• Financial Impact: The receipt of a US\$45 million milestone payment from AstraZeneca represents a substantial financial boost and validates the commercial potential of CMG901.
• Clinical Progress: Advancement to Phase III clinical trials, especially with the first patient dosed, not only de-risks the program but also positions CMG901 closer to potential regulatory approval and market launch. This is a key inflection point for Lepu Biopharma’s value proposition to investors.
• Pipeline Strengthening: Multiple ongoing late-stage trials and regulatory recognitions (breakthrough, orphan, and fast track designations) increase the likelihood of future approvals and commercialization opportunities in major markets.
• Potential Share Price Catalyst: Both the significant milestone payment and the progression of clinical trials could be expected to positively influence Lepu Biopharma’s share price, given the validation of the company’s R&D capabilities and partnership with a leading global pharmaceutical company.

Risk Warning

Despite these positive developments, shareholders should be aware that there is no assurance that CMG901 will ultimately be successfully developed, launched, or commercialized. The company explicitly advises caution in trading its shares as clinical development carries inherent risks and uncertainties.

Board Composition

As of the announcement date, the Board of Lepu Biopharma is composed of Dr. Pu Zhongjie (Chairman and Executive Director), Dr. Sui Ziye (CEO), Ms. Pu Jue and Ms. Qin Yiran (Non-Executive Directors), and Mr. Zhou Demin, Mr. Yang Haifeng, and Mr. Fengmao Hua (Independent Non-Executive Directors).

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence and consider consulting a licensed financial advisor before making investment decisions. The clinical development of pharmaceutical products is subject to significant risks, and there is no guarantee of regulatory approval or commercial success.

View LEPU BIO-B Historical chart here